<DOC>
	<DOCNO>NCT01391481</DOCNO>
	<brief_summary>PFCs ( perfluorocarbon , PFC ) , ideal liquid respiratory medium , special chemical biological property , include high solubility gas , swiftness carry release , low surface tension , high proportion , almost non-absorbing non-metabolic characteristic body . On basis strong animal data suggest efficacy PFC vapor inhalation model lung injury , perform randomized clinical trial compare PFC vapor inhalation conventional mechanical ventilation（CMV）in patient Acute Lung Injury/Acute Respiratory Distress Syndrome（ALI/ARDS） . The investigator apply Invasive Mechanical Ventilation ( IMV ) vaporize perfluorocarbon inhalation , objectively evaluate curative effect acute respiratory distress syndrome , meanwhile assess safety PFC .</brief_summary>
	<brief_title>Perfluorocarbon ( PFC ) Inhalation Treatment Acute Lung Injury/Acute Respiratory Distress Syndrome</brief_title>
	<detailed_description>Based invasive mechanical ventilation ( IMV ) treatment ALI/ARDS , therapeutic action vaporize PFC inhalation evaluate treatment ALI/ARDS patient , safety vaporize PFC inhalation treatment ALI/ARDS . The Test group make time fix quantify inhalation PFC , control group treat inhalation water injection . The general condition patient assess monitor vital sign , hematology test APACHE II score , etc . Main outcome measure include oxygenation index , respiratory mechanic ; secondary outcome include ventilator-free day , 28-day mortality .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<criteria>Age : 1875 year old Some clear risk aetiological agent acute respiratory distress syndrome Acute onset , correspond clinical manifestation PaO2/FiO2 ≤ 300mmHg Chest radiograph chest computerize tomography prompt bilateral pulmonary infiltrate shadow pulmonary capillary wedge pressure ( PCWP ) ≤ 18 mmHg clinical cardiogenic pulmonary edema exclude respiratory rate ( RR ) ≥ 30bpm ( ) respiratory distress require tracheal intubation tracheostomy invasive mechanical ventilation receive invasive mechanical ventilation time ≤ 3 day Age : &lt; 18 year old &gt; 75 year old During early stage treatment , use mechanical ventilation 3 day ALI/ARDS reason Lung parenchyma airway surgery carry within 30 day screen period Severe arrhythmia myocardial ischemia cardiopulmonary resuscitation Systolic blood pressure &lt; 90 mm Hg , maintain stability intravenous infusion vasopressor drug Intubation due interstitial lung disease ( E.g. , sarcoidosis , idiopathic pulmonary fibrosis ) Any active pneumothorax mediastinal emphysema Risk factor lead death within 3 month addition ALI/ARDS screening period ( E.g. , endstage cancer ) Of perfluorocarbon ' allergy Pregnant , breastfeed woman Attending clinical trial within 30 day screen period Severe organ dysfunction ( Marshall score ≥ 3 Sequential Organ Failure Assessment（SOFA） score≥ 3 , include serious liver kidney dysfunction , upper gastrointestinal hemorrhage , etc . ) Acute Physiology Chronic Health Evaluation（APACHE） II score ≥ 30 , high risk death The researcher consider situation suitable case participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Perfluorocarbon</keyword>
	<keyword>Acute Respiratory Distress Syndrome</keyword>
	<keyword>Acute lung injury</keyword>
</DOC>